Biogen Inc.
Biogen Inc is a US-based biotechnology company focused on treatments for neurological and neurodegenerative conditions. Investors should know the company mixes mature revenue-generating drugs for multiple sclerosis and spinal muscular atrophy with a high-profile and sometimes volatile research pipeline. Biogen’s market capitalisation is around $21.44B, which reflects both its commercial products and the market’s view of future approvals and patent timelines. Key drivers include clinical trial results, regulatory decisions, patent expiries and partnerships; these events can move the share price substantially. There is also reputational and regulatory risk following past controversy over Alzheimer’s therapy approvals. Biogen may appeal to investors who want exposure to neuroscience-focused biotech, but suitability depends on risk tolerance, investment horizon and portfolio diversification. This is general educational information only and not personalised investment advice — consider seeking independent financial advice and review the company’s latest filings before making decisions.
Why It's Moving
Biogen Beats Q4 Expectations but Flags 2026 Revenue Dip Amid Pipeline Momentum
- Q4 revenue surprised positively by 3% at $2.28B with Non-GAAP EPS of $1.99 crushing forecasts by 23%, driven by 54% surge in LEQEMBI sales to $134M signaling Alzheimer's therapy traction.
- Growth products jumped 19% for the year, offsetting 7% MS declines, as rare disease revenue climbed 8% via strong SKYCLARYS and ZURZUVAE demand.
- Pipeline heats up with FDA Priority Review for LEQEMBI expansion and Breakthrough Therapy nod for litifilimab, setting stage for multiple Phase 3 wins through 2029.
Biogen Beats Q4 Expectations but Flags 2026 Revenue Dip Amid Pipeline Momentum
- Q4 revenue surprised positively by 3% at $2.28B with Non-GAAP EPS of $1.99 crushing forecasts by 23%, driven by 54% surge in LEQEMBI sales to $134M signaling Alzheimer's therapy traction.
- Growth products jumped 19% for the year, offsetting 7% MS declines, as rare disease revenue climbed 8% via strong SKYCLARYS and ZURZUVAE demand.
- Pipeline heats up with FDA Priority Review for LEQEMBI expansion and Breakthrough Therapy nod for litifilimab, setting stage for multiple Phase 3 wins through 2029.
When is the next earnings date for Biogen Inc. (BIIB)?
Biogen's next earnings date is scheduled for April 30, 2026, covering the Q1 2026 financial results. This follows the recent Q4 2025 report released on February 6, 2026. Executives are expected to discuss the quarter's performance and forward outlook during the earnings call.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biogen's stock, expecting potential growth despite a slightly lower target price.
Financial Health
Biogen is performing well with strong revenue and profits, alongside healthy cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BIIB
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue and Pipeline
Biogen balances established drug sales with pipeline candidates; revenues can provide stability while trial readouts drive outlook, though results may be unpredictable.
Regulatory Catalysts
Regulatory decisions and trial outcomes are key value drivers — positive news can boost sentiment, but setbacks can quickly reverse gains.
Industry Dynamics
Competition, patent lifecycles and pricing pressure shape long-term prospects; consider diversification and risk tolerance before exposure, as biotech can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
